Results 191 to 200 of about 49,941 (320)

Narcolepsy and rapid eye movement sleep

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Since the first description of narcolepsy at the end of the 19th Century, great progress has been made. The disease is nowadays distinguished as narcolepsy type 1 and type 2. In the 1960s, the discovery of rapid eye movement sleep at sleep onset led to improved understanding of core sleep‐related disease symptoms of the disease (excessive ...
Francesco Biscarini, Lucie Barateau, Fabio Pizza, Giuseppe Plazzi, Yves Dauvilliers   +4 more
wiley   +1 more source

Autoimmune limbic encephalitis and anesthesia [PDF]

, 2013
Chrysanthi Batistaki, Kalliopi H Drachtidi, Georgia Kostopanagiotou   +2 more
openalex   +1 more source

The Future of Parasomnias

Journal of Sleep Research, EarlyView.
ABSTRACT Parasomnias are abnormal behaviours or mental experiences during sleep or the sleep–wake transition. As disorders of arousal (DOA) or REM sleep behaviour disorder (RBD) can be difficult to capture in the sleep laboratory and may need to be diagnosed in large communities, new home diagnostic devices are being developed, including actigraphy ...
Claudia Picard‐Deland, Matteo Cesari, Ambra Stefani, Jean‐Baptiste Maranci, Birgit Hogl, Isabelle Arnulf   +5 more
wiley   +1 more source

Autoimmune encephalitis: An emerging entity [PDF]

, 2013
Pyara Ratnayake
openalex   +1 more source

Postneonatal Cerebral Palsy in Europe: Prevalence and Clinical Characteristics According to Contributory Events: An SCPE Study

Paediatric and Perinatal Epidemiology, Volume 39, Issue 3, Page 287-298, March 2025.
ABSTRACT Background Postneonatal cerebral palsy (PNCP) is rare and requires large databases to be studied over time. Objectives To study the time trend of prevalence of PNCP overall and by cause, and to describe the clinical characteristics of children with PNCP according to cause and compared with children with pre/peri/neonatal CP (PPNCP).
Malika Delobel‐Ayoub, Virginie Ehlinger, Dana Klapouszczak, Anja Troha Gergeli, Elodie Sellier, Katalin Hollody, Daniel Virella, Torstein Vik, Célia Perret, Nicolas Vidart d’Egurbide Bagazgoïtia, Karen Horridge, Catherine Arnaud   +11 more
wiley   +1 more source

Scrub typhus‐associated movement and gait disorders: A systematic review with principal component analysis and in silico mechanistic modelling

Tropical Medicine &International Health, EarlyView.
Abstract Background Orientia tsutsugamushi, the causative agent of scrub typhus, is increasingly recognised for its neurological complications. Among these, movement and gait disorders are poorly understood. We systematically examined their clinical spectrum and explored underlying mechanisms through in‐silico protein–protein interaction modelling ...
Ritwick Mondal, Shramana Deb, Mrinmay Dhauria, Purbita Sen, Vramanti Sarkar, Shramana Sarkar, Dipanjan Chowdhury, Durjoy Lahiri, Jayanta Roy, Julián Benito‐León   +9 more
wiley   +1 more source

Unexpected Remyelination in the Absence of Matrix Metalloproteinase 7

Glia, Volume 73, Issue 6, Page 1288-1306, June 2025.
Main Points MMP7 is not essential for demyelination and remyelination in the cuprizone model. MMP7‐/‐ mice fibronectin aggregates do not accumulate in the remyelination phase. MMP7‐/‐ mice have lower levels of fibronectin and hyaluronan after chronic demyelination.
Rianne P. Gorter, Andrea J. Arreguin, Wendy Oost, Jenny C. de Jonge, Harm H. Kampinga, Sandra Amor, Holly Colognato, Wia Baron   +7 more
wiley   +1 more source

Encephalitis Lethargica: An Autoimmune Disease

, 2004
J Gordon Millichap
openalex   +1 more source

Autoimmune Encephalitis—Antibody Targets and Their Potential Pathogenicity in Immunotherapy-responsive Syndromes [PDF]

, 2013
Katarzyna D. Bera, Angela Vincent, Sarosh R. Irani   +2 more
openalex   +1 more source

Olanzapine enabled rechallenge after lorlatinib‐induced psychosis: A case report

Psychiatry and Clinical Neurosciences Reports, Volume 4, Issue 2, June 2025.
Antipsychotic treatment for lorlatinib‐induced psychotic symptoms enables lorlatinib rechallenge and targeted therapy for lung cancer. Abstract Background Lorlatinib is a third‐generation tyrosine kinase inhibitor for anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC).
Akiyoshi Yokode, Masaki Fujiwara, Yuko Nakamura, Kadoaki Ohashi, Shinji Sakamoto, Manabu Takaki   +5 more
wiley   +1 more source